Serum Valproic Acid Level (Total Valproate)
Order a serum valproic acid level, which measures total valproate concentration in blood, typically drawn as a trough level (just before the next dose) for patients on standard formulations. 1
Test Specifications
The laboratory test measures total serum valproate concentration in plasma or serum. According to the FDA label, the therapeutic range for epilepsy is 50 to 100 mcg/mL of total valproate, though some patients achieve control outside this range 1.
Timing of Blood Draw
Standard formulations (immediate-release, delayed-release): Draw trough level immediately before the next scheduled dose (typically 21-24 hours after last dose for once-daily dosing) 2
Extended-release (Depakote ER) dosed in morning: Sample 21-24 hours later yields concentration within 3% of true trough 2
Extended-release dosed in evening (e.g., 8 PM):
Critical Interpretation Considerations
The FDA label emphasizes a crucial limitation: monitoring total serum valproate may not provide a reliable index of bioactive drug due to concentration-dependent protein binding 1. Specifically:
- At 40 mcg/mL: ~10% free (active) fraction
- At 130 mcg/mL: ~18.5% free fraction
- Higher free fractions occur in elderly, hyperlipidemic patients, and those with hepatic/renal disease 1
This means two patients with identical total levels may have vastly different clinical responses. Research confirms poor correlation between plasma concentration and clinical response exists 3.
Laboratory Methods
Multiple validated methods exist:
- Enzyme immunoassay (EMIT) - most common, automated 4
- High-performance liquid chromatography (HPLC) 5
- Gas-liquid chromatography (GLC) 4
Important: EDTA or fluoride/oxalate anticoagulants can bias results toward falsely elevated values; serum is preferred 4.
Clinical Pitfalls
Research demonstrates that most valproic acid level measurements are ordered inappropriately—one audit found only 15% of tests had appropriate indications and 29% were drawn at correct times 6. This represents significant healthcare waste.
Appropriate Indications for Testing:
- Suspected toxicity or overdose
- Inadequate seizure control despite adequate dosing
- Suspected non-adherence
- Drug interactions affecting valproate metabolism
- Hepatic or renal impairment
- Pregnancy (altered pharmacokinetics)
When NOT to routinely test:
- Stable patients with good seizure control
- Without clinical indication for dose adjustment
- Random timing without consideration of pharmacokinetics
The relationship between concentration and clinical response remains poorly documented 1, so clinical assessment must always supersede laboratory values when making treatment decisions.